Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Editorial
. 2011 Apr;96(4):491-3.
doi: 10.3324/haematol.2011.043208.

Acute myeloid leukemia with monosomal karyotype at the far end of the unfavorable prognostic spectrum

Dimitri A Breems, Bob Löwenberg
Editorial

Acute myeloid leukemia with monosomal karyotype at the far end of the unfavorable prognostic spectrum

Dimitri A Breems et al. Haematologica. 2011 Apr.
No abstract available

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Overall survival of patients with acute myeloid leukemia (AML) and non-core-binding-factor chromosomal abnormalities. (A) Survival in relation to numbers of autosomal chromosomal monosomies (none, 1, and ≥2 ms). (B) Survival in relation to ‘monosomal karyotype’ (in figure designated as MI) as defined by Breems et al. and/or ‘complex karyotype with ≥3 cytogenetic clonal abnormalities’ (CK). Reprinted with permission. ©2008 American Society of Clinical Oncology. All rights reserved.” Breems D et al. J Clin Oncol 2008;26(29):4791–7.
Figure 2.
Figure 2.
Overall survival of four prognostic subcategories of acute myeloid leukemia (AML) aggregated according to cytogenetics. Core-binding-factor (CBF) abnormalities. Normal karyotype (CN). Non-CBF abnormalities but 'monosomal karyotype' negative (in figure designated as MI−) and non-CBF abnormalities but 'monosomal karyotype' positive (in figure designated as MI+). MK refers to ≥2 autosomal monosomies or one autosomal monosomy with at least one structural abnormality. Breems D et al. J Clin Oncol 2008; 26(29):4791–7.
See this image and copyright information in PMC

Comment on

References

    1. Lowenberg B, Downing JR, Burnett A. Acute myeloid leukemia. N Engl J Med. 1999;341(14):1051–62. - PubMed
    1. Dohner H, Estey EH, Amadori S, Appelbaum FR, Buchner AK, Burnett AK, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115(3):453–74. - PubMed
    1. Burnett A, Wetzler M, Lowenberg B. Therapeutic Advances in Acute Myeloid Leukemia. J Clin Oncol. 2011;29(5):487–94. - PubMed
    1. Xie B, Othus M, Medeiros BC, Fang M, Appelbaum FR, Estey EH. Influence of residual normal metaphases in acute myeloid leukemia patients with monosomal karyotype. Haematologica. 2011;96(4):631–2. - PMC - PubMed
    1. Breems DA, Van Putten WL, De Greef GE, Van Zelderen-Bhola SL, Gerssen-Schoorl KBJ, Mellink CHM, et al. Monosomal karyotype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J Clin Oncol. 2008;26(29):4791–7. - PubMed